While evidence on EREG and AREG secretion from CAFs in response to EGFR-targeted therapy is limited, it has been shown that EREG and AREG can be overexpressed and secreted from CAFs in colitis-associated CRC as well as other cancer types to promote tumor progression [90–92]. The gene discussed is EGFR; the disease is cancer.